Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome

American Journal of Medicine

Volumn 104, Issue 5, 1998, Pages 422-430

  Termanini, Basel ^a   Gibril, Fathia ^a   Sutliff, Vincent E ^a   Yu, Fang ^a   Venzon, David J ^b   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; VITAMIN B GROUP;

ACHLORHYDRIA; ARTICLE; DISEASE SEVERITY; ENZYME INHIBITION; FOLIC ACID BLOOD LEVEL; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STOMACH ACID SECRETION; VITAMIN DEFICIENCY; ZOLLINGER ELLISON SYNDROME;

ACHLORHYDRIA; ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; DRUG MONITORING; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; TIME FACTORS; VITAMIN B 12; VITAMIN B 12 DEFICIENCY; ZOLLINGER-ELLISON SYNDROME;

EID: 0032076634     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00087-4     Document Type: Article

References (68)

1. 1. Clissold SP, Campoli-Richards DM. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential on peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 1986;32:15-47.
2. 2. Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1994;48: 91-132.
3. 3. Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994;48:404-430.
4. 4. Kahrilas PJ, Hogan WJ. Gastroesophageal reflux disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease. 5th ed. Philadelphia, Pa: WB Saunders;1993;378-401.
5. 5. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903-912.
6. 6. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621-628.
7. 7. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993;104:1356-1370.
8. 12 malabsorption and omeprazole therapy. J Am Coll Nutr. 1994;13:544-545.
9. 9. Maton P. Risks of hypergastrinemia. Dig Dis Sci. 1995;13:1-2.
10. 10. Maton PN, Dayal Y. Clinical implications of hypergastrinemia. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Acid-related Disorders. Armonk, NY: Academic Research Associates; 1991;213-246.
11. 11. Ekman L, Hansson E, Havu N, et al. Toxicological studies on omeprazole. Scand J Gastroenterol. 1985;20 (suppl 108):53-69.
12. 12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14:288-292.
13. 12 absorption. J Am Coll Nutr. 1994;13:584-591.
14. 12). In: Johnson LR, Alpers DH, Christensen J, et al, eds. Physiology of the Gastrointestinal Tract. 3rd ed. New York: Raven Press; 1994:1997-2026.
15. 15. Festen HP. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol. 1991;26:1-7.
16. 16. Babior BM. Metabolic aspects of folic acid and cobalamin. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. William's Hematology. 5th ed. New York: McGraw-Hill; 1996:380-393.
17. 17. Koop H. Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther. 1992;6:399-406.
18. 12). Ann Intern Med. 1994;120:211-215.
19. 19. Festen H, Tertoolen J. Malabsorption of protein-bound but not unbound cobalamin during treatment with omeprazole. Gastroenterology. 1988;94:A125. Abstract.
20. 20. Kittang E, Aadland E, Schjonsby H, Rohss K. The effect of omeprazole on gastric acidity and the absorption of liver cobalamins. Scand J Gastroenterol. 1987;22:156-160.
21. 21. Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology. 1989;97:827-836.
22. 22. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993;7:597-610.
23. 23. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research. Basel, Switzerland: S Karger; 1995:240-257.
24. 24. Jensen RT, Fraker DL. Zollinger-Ellison syndrome: advances in treatment of the gastric hypersecretion and the gastrinoma. JAMA. 1994;271:1-7.
25. 25. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, et al, eds. The Pancreas: Biology, Pathobiology and Disease. 2nd ed. New York, NY: Raven Press; 1993:931-978.
26. 26. Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199-206.
27. 27. Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: a prospective study. Ann Intern Med. 1989;111:713-722.
28. 28. Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg. 1993;17:468-480.
29. 29. Orbuch M, Doppman JL, Strader DB, et al. Imaging for pancreatic endocrine tumor localization: recent advances. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research. Basel, Switzerland: S Karger; 1995:268-281.
30. 30. Cherner JA, Doppman JL, Norton JA, et al. Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Ann Intern Med. 1986;105:841-847.
31. 31. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med. 1994;97:436-444.
32. 32. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103:1498-1508.
33. 33. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology. 1990;98:341-346.
34. 34. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637-1649.
35. 35. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, Conn: Appleton & Lange; 1990:1-329.
36. 36. Kittang E, Aadlang E, Schonsby H. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man. Gut. 1985;26:594-598.
37. 37. Shimoda SS, Saunders DR, Rubin CE. The Zollinger-Ellison syndrome with steatorrhea. II. The mechanism of fat and vitamin B 12 malabsorption. Gastroenterology. 1968;55(6):705-723.
38. 38. Shafer RB, Ripley D, Swaim WR, et al. Hematologic alterations following partial gastrectomy. Am J Med Sci. 1973;266:240-248.
39. 12 deficiency after gastric surgery. Ann Intern Med. 1996;124:469-476.
40. 40. Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60:2-11.
41. 41. Joosten E, van den Berg A, Riezler R, et al. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr. 1993;58:468-476.
42. 12 in patients with hypochlorhydria and achlorhydria and after gastric resection. Gastroenterology. 1973;64:913-919.
43. 12. Dig Dis Sci. 1979;24:397-402.
44. 12 malabsorption with antibiotics in atrophic gastritis. Gastroenterology. 1991;101:1039-1045.
45. 45. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106:615-623.
46. 46. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54-59.
47. 47. Streeter AM, Goulston KJ, Bathur FA, et al. Cimetidine and malabsorption of cobalamin. Dig Dis Sci. 1982;27:13-16.
48. 48. Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci. 1980;25:188-191.
49. 49. Salom IL, Silvis SE, Doscherholmen A. Effect of cimetidine on the absorption of vitamin B12. Scand J Gastroenterol. 1982;17:129-131.
50. 50. Belaiche J, Cattan D, Zittoun J, et al. Effect of ranitidine on cobalamin absorption. Dig Dis Sci. 1983;28:667-668. Letter.
51. 51. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther. 1987;1:239-251.
52. 52. Vinayek R, Howard JM, Maton PN, et al. Famotidine in the therapy of gastric hypersecretory states. Am J Med. 1986;81:49-59.
53. 53. Jensen RT, Collen MJ, McArthur KE, et al. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. In: Misiewicz JJ, Wood JR, eds. Ranitidine: Therapeutic Advances. Amsterdam, Netherlands: Excerpta Medica; 1984:168-198.
54. 54. McArthur KE, Raufman JP, Seaman JJ, et al. Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome. Gastroenterology. 1987;93:69-76.
55. 55. Bardram L, Stadil F. Effects of omeprazole on acid secretion and acid related symptoms in patients with Zollinger-Ellison syndrome. Scand J Gastroenterol. 1989;166 (suppl):95-100.
56. 56. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with the Zollinger-Ellison syndrome. Dig Dis Sci. 1991;36:394-404.
57. 57. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther. 1993;7 (Suppl 1):41-50.
58. 58. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg. 1992;215:8-18.
59. 59. Jensen RT. Gastrin-producing tumors. Cancer Treat Res. 1997;89: 293-334.
60. 60. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. NEJM. 1988;318:1720-1728.
61. 61. Carmel R. Pernicious anemia. The expected findings of very low serum cobalamin levels, anemia, and macrocytosis are often lacking. Arch Intern Med. 1988;148:1712-1714.
62. 62. Carmel R, Sinow RM, Karnaze DS. Atypical cobalamin deficiency. Subtle biochemical evidence of deficiency is commonly demonstrable in patients without megaloblastic anemia and is often associated with protein-bound cobalamin malabsorption. J Lab Clin Med. 1987;109:454-463.
63. 12 levels. Ann Intern Med. 1996;124:299-304.
64. 64. Hall CA, Green-Colligan PD, Begley JA. The role of cobalamin in synthesis of protein and immunoglobulins by human peripheral lymphocytes. Nutr Res. 1981;1:349-361.
65. 12) deficiency. Acta Med Scand. 1963;174:193-200.
66. 66. Kafetz K. Immunoglobulin deficiency responding to vitamin B12 in two elderly patients with megaloblastic anaemia. Postgrad Med J. 1985;61:1065-1066.
67. 67. Carmel R. Subtle cobalamin deficiency. Ann Intern Med. 1996;124: 338-340.
68. 68. Lamberts R, Creutzfeldt W, Stockmann F, et al. Long term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion. 1988;39:126-135.